Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD3+/CD19+ Depleted Matched and Mismatched Unrelated Donor Hematopoietic Stem Cell Transplant with Targeted T Cell Addback Is Associated with Excellent Outcomes in Pediatric Patients with Nonmalignant Hematologic Disorders.
Oved JH, Wang Y, Barrett DM, Levy EM, Huang Y, Monos DS, Grupp SA, Bunin NJ, Olson TS. Oved JH, et al. Among authors: levy em. Biol Blood Marrow Transplant. 2019 Mar;25(3):549-555. doi: 10.1016/j.bbmt.2018.10.003. Epub 2018 Oct 9. Biol Blood Marrow Transplant. 2019. PMID: 30312755 Free PMC article.
In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy.
Sanchez MB, Vasconcelos Cordoba B, Pavlovsky C, Moiraghi B, Varela A, Custidiano R, Fernandez I, Freitas MJ, Ventriglia MV, Bendek G, Mariano R, Mela Osorio MJ, Pavlovsky MA, García de Labanca A, Foncuberta C, Giere I, Vera M, Juni M, Mordoh J, Sanchez Avalos JC, Levy EM, Bianchini M. Sanchez MB, et al. Among authors: levy em. Front Immunol. 2023 Sep 25;14:1241600. doi: 10.3389/fimmu.2023.1241600. eCollection 2023. Front Immunol. 2023. PMID: 37818372 Free PMC article. Clinical Trial.
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal.
Pavlovsky C, Vasconcelos Cordoba B, Sanchez MB, Moiraghi B, Varela A, Custidiano R, Fernandez I, Freitas MJ, Ventriglia MV, Bendek G, Mariano R, Mela Osorio MJ, Pavlovsky MA, de Labanca AG, Foncuberta C, Giere I, Vera M, Juni M, Mordoh J, Sanchez Avalos JC, Cueto G, Miranda S, Levy EM, Bianchini M. Pavlovsky C, et al. Among authors: levy em. J Hematol Oncol. 2023 Apr 29;16(1):43. doi: 10.1186/s13045-023-01440-6. J Hematol Oncol. 2023. PMID: 37120577 Free PMC article.
Phenotypic and functional analysis in HER2+ targeted therapy of human NK cell subpopulation according to the expression of FcεRIγ and NKG2C in breast cancer patients.
Bordignon MB, Pesce Viglietti AI, Juliá EP, Sanchez MB, Rölle A, Mandó P, Sabatini L, Ostinelli A, Rizzo MM, Barrio MM, Mordoh J, Fainboim L, Levy EM. Bordignon MB, et al. Among authors: levy em. Cancer Immunol Immunother. 2023 Aug;72(8):2687-2700. doi: 10.1007/s00262-023-03448-w. Epub 2023 Apr 21. Cancer Immunol Immunother. 2023. PMID: 37081323 Free PMC article.
Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients.
Juliá EP, Mandó P, Rizzo MM, Cueto GR, Tsou F, Luca R, Pupareli C, Bravo AI, Astorino W, Mordoh J, Martín C, Levy EM. Juliá EP, et al. Among authors: levy em. Cancer Immunol Immunother. 2019 Oct;68(10):1585-1596. doi: 10.1007/s00262-019-02391-z. Epub 2019 Sep 12. Cancer Immunol Immunother. 2019. PMID: 31515670 Free PMC article.
72 results